{
    "nct_id": "NCT05150652",
    "official_title": "Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer",
    "inclusion_criteria": "* Pathologically confirmed invasive breast cancer, clinically stage I-II.\n* Clinically lymph node negative\n* Eligible for anti-endocrine treatment (per medical oncologist)\n* Postmenopausal women\n* Ability to understand and the willingness to sign a written informed consent document\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Progesterone receptor negativity\n* High grade tumor\n* Synchronous non-breast malignancy\n* Receiving any other investigational agents that could impact the efficacy of this trial regimen\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Anastrozole, Letrozole, Exemestane, Tamoxifen or other agents used in study\n* Uncontrolled intercurrent illness\n* Medical, psychiatric or other condition and/or social situations that would limit compliance with study requirements",
    "miscellaneous_criteria": ""
}